Sigma Biotech Profile
Key Indicators
- Authorised Capital ₹ 2.50 M
- Paid Up Capital ₹ 0.10 M
- Company Age 14 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth %
- Profit Growth 18.94%
- Ebitda 18.55%
- Net Worth -0.80%
- Total Assets -0.03%
About Sigma Biotech
Sigma Biotech Private Limited (SBPL) is a Private Limited Indian Non-Government Company incorporated in India on 19 May 2010 and has a history of 14 years and nine months. Its registered office is in Delhi, India.
The Corporate was formerly known as Sigma Infraprop Private Limited. The Company is engaged in the Chemicals And Materials Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 2.50 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Rahul Goyal and Shammi Garg serve as directors at the Company.
Company Details
- Location
Delhi, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24297DL2010PTC202904
- Company No.
202904
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
19 May 2010
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Delhi
Industry
Who are the key members and board of directors at Sigma Biotech?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Rahul Goyal  | Director | 19-May-2010 | Current |
| Shammi Garg | Director | 27-Apr-2015 | Current |
Financial Performance of Sigma Biotech.
Sigma Biotech Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a substantial improvement in profitability, with a 18.94% increase in profit. The company's net worth dipped by a decrease of 0.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Sigma Biotech?
In 2023, Sigma Biotech had a promoter holding of 10.00% and a public holding of 90.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Gama Infraprop Private LimitedRahul Goyal is a mutual person
Magnum International LlpRahul Goyal is a mutual person
- Vector Infraprop Private Limited
Rahul Goyal is a mutual person
- Vistaar Chemicals Private Limited
Rahul Goyal is a mutual person
- Par Estates Private Limited
Rahul Goyal is a mutual person
- Amrit Shyam Properties Pvt Ltd
Rahul Goyal is a mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Sigma Biotech?
Unlock and access historical data on people associated with Sigma Biotech, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Sigma Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Sigma Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
